{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:28:54Z","timestamp":1787671734183,"version":"build-2736575974"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03154-4","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:29:19Z","timestamp":1785504559000},"page":"1791-1819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current therapeutic interventions to target cancer stem cells for metastasis"],"prefix":"10.1007","volume":"31","author":[{"given":"Priyancka","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash C.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagmohan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9768-1644","authenticated-orcid":false,"given":"Anil Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"1","key":"3154_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"3154_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10434-000-0262-z","volume":"7","author":"I Bedrosian","year":"2000","unstructured":"Bedrosian I et al (2000) Incidence of sentinel node metastasis in patients with thin primary melanoma (# 1 mm) with vertical growth phase. Ann Surg Oncol 7:262\u2013267","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3154_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ddmod.2005.04.001","volume":"2","author":"A Eger","year":"2005","unstructured":"Eger A, Mikulits W (2005) Models of epithelial\u2013mesenchymal transition. Drug Discov Today Dis Models 2(1):57\u201363","journal-title":"Drug Discov Today Dis Models"},{"issue":"4","key":"3154_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massague","year":"2021","unstructured":"Massague J, Ganesh K (2021) Metastasis-initiating cells and ecosystems. Cancer Discov 11(4):971\u2013994","journal-title":"Cancer Discov"},{"issue":"3","key":"3154_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29(3):212\u2013226","journal-title":"Trends Cell Biol"},{"issue":"3","key":"3154_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-018-0134-8","volume":"16","author":"RL Anderson","year":"2019","unstructured":"Anderson RL et al (2019) A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol 16(3):185\u2013204","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3154_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178\u2013196","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3154_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T et al (2022) The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther 7(1):376","journal-title":"Signal Transduct Target Ther"},{"key":"3154_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fonc.2020.00928","volume":"10","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Taouk GM (2020) A potential role of YAP\/TAZ in the interplay between metastasis and metabolic alterations. Front Oncol 10:928","journal-title":"Front Oncol"},{"key":"3154_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.isci.2019.07.049","volume":"19","author":"LJ Wheeler","year":"2019","unstructured":"Wheeler LJ et al (2019) Multi-omic approaches identify metabolic and autophagy regulators important in ovarian cancer dissemination. iScience 19:474\u2013491","journal-title":"iScience"},{"issue":"36","key":"3154_CR11","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1038\/s41388-018-0341-x","volume":"37","author":"W Li","year":"2018","unstructured":"Li W, Ng JM-K, Wong CC et al (2018) Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene 37(36):4903\u20134920","journal-title":"Oncogene"},{"issue":"7577","key":"3154_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature15726","volume":"527","author":"E Piskounova","year":"2015","unstructured":"Piskounova E et al (2015) Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527(7577):186\u2013191","journal-title":"Nature"},{"issue":"3","key":"3154_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.molcel.2018.01.001","volume":"69","author":"X Li","year":"2018","unstructured":"Li X et al (2018) Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol Cell 69(3):480\u2013492","journal-title":"Mol Cell"},{"issue":"4","key":"3154_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/CM9.0000000000003738","volume":"139","author":"S Chen","year":"2026","unstructured":"Chen S, Zhang S, Shi Y et al (2026) Microenvironment crosstalk and immune evasion of circulating tumor cells: from mechanism to clinical significance. Chin Med J 139(4):515\u2013535. https:\/\/doi.org\/10.1097\/CM9.0000000000003738","journal-title":"Chin Med J"},{"issue":"4","key":"3154_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massagu\u00e9","year":"2021","unstructured":"Massagu\u00e9 J, Ganesh K (2021) Metastasis-initiating cells and ecosystems. Cancer Discov 11(4):971\u2013994. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0010","journal-title":"Cancer Discov"},{"issue":"1","key":"3154_CR16","doi-asserted-by":"publisher","first-page":"14041","DOI":"10.1038\/ncomms14041","volume":"8","author":"Y Wei","year":"2017","unstructured":"Wei Y et al (2017) Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun 8(1):14041","journal-title":"Nat Commun"},{"issue":"8","key":"3154_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1101\/gad.277681.116","volume":"30","author":"T Celi\u00e0-Terrassa","year":"2016","unstructured":"Celi\u00e0-Terrassa T, Kang Y (2016) Distinctive properties of metastasis-initiating cells. Genes Dev 30(8):892\u2013908","journal-title":"Genes Dev"},{"issue":"1","key":"3154_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H et al (2025) Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther 10(1):248. https:\/\/doi.org\/10.1038\/s41392-025-02360-2","journal-title":"Signal Transduct Target Ther"},{"key":"3154_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11010-015-2595-8","volume":"411","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang J, Xing H et al (2016) Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol Cell Biochem 411:331\u2013340","journal-title":"Mol Cell Biochem"},{"key":"3154_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0797-x","author":"R Butti","year":"2018","unstructured":"Butti R, Das S, Gunasekaran VP et al (2018) Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-018-0797-x","journal-title":"Mol Cancer"},{"issue":"1","key":"3154_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, Yang Y, Li Q et al (2018) Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res 6(1):10","journal-title":"Biomark Res"},{"key":"3154_CR22","unstructured":"Alberts B (2002) \u201cMolecular biology of the cell 4th edition\u201d (No Title)"},{"issue":"3","key":"3154_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s43018-021-00181-0","volume":"2","author":"M Esposito","year":"2021","unstructured":"Esposito M, Ganesan S, Kang Y (2021) Emerging strategies for treating metastasis. Nat Rev Cancer 2(3):258\u2013270","journal-title":"Nat Rev Cancer"},{"key":"3154_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/or.2024.1435922","author":"Z Xu","year":"2024","unstructured":"Xu Z, Jiang G, Dai J (2024) Tumor therapeutics in the era of \u2018RECIST\u2019: past, current insights, and future prospects. Oncol Rev. https:\/\/doi.org\/10.3389\/or.2024.1435922","journal-title":"Oncol Rev"},{"issue":"4","key":"3154_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/nnm.12.22","volume":"7","author":"S Vinogradov","year":"2012","unstructured":"Vinogradov S, Wei X (2012) Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 7(4):597\u2013615","journal-title":"Nanomedicine"},{"issue":"4","key":"3154_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275\u2013284","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3154_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3892\/ol.2017.6164","volume":"14","author":"H Du","year":"2017","unstructured":"Du H, Zhou B, Zhang H et al (2017) Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells. Oncol Lett 14(1):427\u2013432","journal-title":"Oncol Lett"},{"issue":"3","key":"3154_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2010.09.043","volume":"143","author":"LA Gilbert","year":"2010","unstructured":"Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143(3):355\u2013366","journal-title":"Cell"},{"issue":"1","key":"3154_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S et al (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165\u2013178","journal-title":"Cell"},{"key":"3154_CR30","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.06.09","author":"I Arozarena","year":"2017","unstructured":"Arozarena I, Wellbrock C (2017) Overcoming resistance to BRAF inhibitors. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm.2017.06.09","journal-title":"Ann Transl Med"},{"issue":"4","key":"3154_CR31","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","volume":"13","author":"NC Turner","year":"2012","unstructured":"Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13(4):e178\u2013e185","journal-title":"Lancet Oncol"},{"issue":"1","key":"3154_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000454696","volume":"33","author":"E Pachmayr","year":"2017","unstructured":"Pachmayr E, Treese C, Stein U (2017) Underlying mechanisms for distant metastasis-molecular biology. Visc Med 33(1):11\u201320","journal-title":"Visc Med"},{"issue":"6","key":"3154_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nrclinonc.2009.44","volume":"6","author":"K Pantel","year":"2009","unstructured":"Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6(6):339\u2013351","journal-title":"Nat Rev Clin Oncol"},{"issue":"42","key":"3154_CR34","doi-asserted-by":"publisher","first-page":"44191","DOI":"10.18632\/oncotarget.6176","volume":"6","author":"T Wang","year":"2015","unstructured":"Wang T et al (2015) Cancer stem cell targeted therapy: progress amid controversies. Oncotarget 6(42):44191","journal-title":"Oncotarget"},{"key":"3154_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-018-0533-1","volume":"19","author":"G Kaur","year":"2018","unstructured":"Kaur G, Sharma P, Dogra N et al (2018) Eradicating cancer stem cells: concepts, issues, and challenges. Curr Treat Options Oncol 19:1\u201323","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"3154_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.176","volume":"3","author":"W Manni","year":"2022","unstructured":"Manni W, Min W (2022) Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm (Beijing) 3(4):e176","journal-title":"MedComm (Beijing)"},{"key":"3154_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","author":"Z Lei","year":"2023","unstructured":"Lei Z et al (2023) Understanding and targeting resistance mechanisms in cancer. MedComm. https:\/\/doi.org\/10.1002\/mco2.265","journal-title":"MedComm"},{"issue":"1","key":"3154_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L et al (2020) Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 5(1):8","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"3154_CR39","first-page":"38","volume":"18","author":"S Warner","year":"2004","unstructured":"Warner S (2004) Diagnostics+ therapy= theranostics: strategy requires teamwork, partnering, and tricky regulatory maneuvering. Scientist 18(16):38\u201340","journal-title":"Scientist"},{"issue":"7","key":"3154_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2017.24","volume":"2","author":"H Chen","year":"2017","unstructured":"Chen H, Zhang W, Zhu G et al (2017) Rethinking cancer nanotheranostics. Nat Rev Mater 2(7):1\u201318","journal-title":"Nat Rev Mater"},{"issue":"2","key":"3154_CR41","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/nn2045246","volume":"6","author":"Z Fan","year":"2012","unstructured":"Fan Z, Shelton M, Singh AK et al (2012) Multifunctional plasmonic shell\u2013magnetic core nanoparticles for targeted diagnostics, isolation, and photothermal destruction of tumor cells. ACS Nano 6(2):1065\u20131073","journal-title":"ACS Nano"},{"issue":"6","key":"3154_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2217\/nnm.09.44","volume":"4","author":"MS Muthu","year":"2009","unstructured":"Muthu MS, Rajesh CV, Mishra A et al (2009) Stimulus-responsive targeted nanomicelles for effective cancer therapy. Nanomedicine 4(6):657\u2013667","journal-title":"Nanomedicine"},{"issue":"9","key":"3154_CR43","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33(9):941\u2013951","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3154_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7150\/thno.7193","volume":"4","author":"H Kobayashi","year":"2014","unstructured":"Kobayashi H, Watanabe R, Choyke PL (2014) Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4(1):81","journal-title":"Theranostics"},{"issue":"18","key":"3154_CR45","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2217\/nnm-2018-0443","volume":"14","author":"A Reda","year":"2019","unstructured":"Reda A, Hosseiny S, El-Sherbiny IM (2019) Next-generation nanotheranostics targeting cancer stem cells. Nanomedicine 14(18):2487\u20132514","journal-title":"Nanomedicine"},{"key":"3154_CR46","doi-asserted-by":"crossref","unstructured":"R Hirulkar N Chaurawal FS Alhodieb H Barkat S Preet K Raza 2024 Nanotheranostics: clinical status, toxicity, regulatory consideration, and future prospects Nanotheranostics for diagnosis and therapy Springer 249 285","DOI":"10.1007\/978-981-97-3115-2_10"},{"issue":"9","key":"3154_CR47","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.7150\/thno.15335","volume":"6","author":"SD Jo","year":"2016","unstructured":"Jo SD, Ku SH, Won Y-Y et al (2016) Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy. Theranostics 6(9):1362","journal-title":"Theranostics"},{"issue":"7089","key":"3154_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature04688","volume":"441","author":"TS Zimmermann","year":"2006","unstructured":"Zimmermann TS et al (2006) RNAi-mediated gene silencing in non-human primates. Nature 441(7089):111\u2013114","journal-title":"Nature"},{"issue":"10","key":"3154_CR49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","volume":"61","author":"Y-K Oh","year":"2009","unstructured":"Oh Y-K, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61(10):850\u2013862","journal-title":"Adv Drug Deliv Rev"},{"issue":"28","key":"3154_CR50","doi-asserted-by":"publisher","first-page":"23441","DOI":"10.1021\/acsami.7b05766","volume":"9","author":"S Nakki","year":"2017","unstructured":"Nakki S, Martinez JO, Evangelopoulos M et al (2017) Chlorin e6 functionalized theranostic multistage nanovectors transported by stem cells for effective photodynamic therapy. ACS Appl Mater Interfaces 9(28):23441\u201323449","journal-title":"ACS Appl Mater Interfaces"},{"issue":"14","key":"3154_CR51","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1039\/C6NR09090G","volume":"9","author":"JS Park","year":"2017","unstructured":"Park JS, Park W, Kang AY et al (2017) Multi-functional nanotracers for image-guided stem cell gene therapy. Nanoscale 9(14):4665\u20134676","journal-title":"Nanoscale"},{"key":"3154_CR52","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s11095-016-2021-2","volume":"33","author":"L Chen","year":"2016","unstructured":"Chen L, Fu C, Deng Y et al (2016) A pH-sensitive nanocarrier for tumor targeting: delivery of ruthenium complex for tumor theranostic by pH-sensitive nanocapsule. Pharm Res 33:2989\u20132998","journal-title":"Pharm Res"},{"key":"3154_CR53","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1208\/s12249-014-0142-7","volume":"15","author":"R Roggers","year":"2014","unstructured":"Roggers R, Kanvinde S, Boonsith S et al (2014) The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal. AAPS PharmSciTech 15:1163\u20131171","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3154_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nbt927","volume":"22","author":"P Alivisatos","year":"2004","unstructured":"Alivisatos P (2004) The use of nanocrystals in biological detection. Nat Biotechnol 22(1):47\u201352","journal-title":"Nat Biotechnol"},{"issue":"9","key":"3154_CR55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nm1096","volume":"10","author":"EB Voura","year":"2004","unstructured":"Voura EB, Jaiswal JK, Mattoussi H et al (2004) Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10(9):993\u2013998","journal-title":"Nat Med"},{"issue":"21","key":"3154_CR56","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1021\/ac901960d","volume":"81","author":"L Xiong","year":"2009","unstructured":"Xiong L, Chen Z, Tian Q et al (2009) High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors. Anal Chem 81(21):8687\u20138694","journal-title":"Anal Chem"},{"issue":"4","key":"3154_CR57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/cmmi.393","volume":"5","author":"L Mart\u00ed\u2010Bonmat\u00ed","year":"2010","unstructured":"Mart\u00ed\u2010Bonmat\u00ed L, Sopena R, Bartumeus P et al (2010) Multimodality imaging techniques. Contrast Media Mol Imaging 5(4):180\u2013189","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"3154_CR58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2011.10.023","volume":"159","author":"X-X Zhang","year":"2012","unstructured":"Zhang X-X, Eden HS, Chen X (2012) Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release 159(1):2\u201313","journal-title":"J Control Release"},{"issue":"7","key":"3154_CR59","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/pros.23311","volume":"77","author":"Z Nov\u00e1kov\u00e1","year":"2017","unstructured":"Nov\u00e1kov\u00e1 Z et al (2017) Novel monoclonal antibodies recognizing human prostate\u2010specific membrane antigen (PSMA) as research and theranostic tools. Prostate 77(7):749\u2013764","journal-title":"Prostate"},{"issue":"6079","key":"3154_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1126\/science.1217622","volume":"336","author":"VB Pinheiro","year":"1979","unstructured":"Pinheiro VB et al (1979) Synthetic genetic polymers capable of heredity and evolution. Science 336(6079):341\u2013344","journal-title":"Science"},{"issue":"1","key":"3154_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40364-019-0178-7","volume":"7","author":"D Liu","year":"2019","unstructured":"Liu D (2019) Cancer biomarkers for targeted therapy. Biomark Res 7(1):25","journal-title":"Biomark Res"},{"issue":"1","key":"3154_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu F et al (2021) Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther 6(1):307","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3154_CR63","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q et al (2024) Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther 9(1):128","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"3154_CR64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/2159-8290.CD-NB2015-121","volume":"5","author":"JY Tang","year":"2015","unstructured":"Tang JY (2015) Hedgehog inhibitor approved for BCC. Cancer Discov 5(10):1011\u20131011. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2015-121","journal-title":"Cancer Discov"},{"key":"3154_CR65","unstructured":"\u201cApproval of the first Hedgehog pathway inhibitor for invasive basal cell carcinomas|Dermatology|Stanford Medicine.\u201d Accessed: Jun. 02, 2026. [Online]. Available: https:\/\/med.stanford.edu\/dermatology\/research\/hedgehog_2012.html"},{"issue":"5","key":"3154_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen CDK, Yi C (2019) YAP\/TAZ signaling and resistance to cancer therapy. Trends Cancer 5(5):283\u2013296","journal-title":"Trends Cancer"},{"key":"3154_CR67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.phrs.2015.11.025","volume":"103","author":"S Ye","year":"2016","unstructured":"Ye S, Eisinger-Mathason TSK (2016) Targeting the Hippo pathway: clinical implications and therapeutics. Pharmacol Res 103:270\u2013278","journal-title":"Pharmacol Res"},{"issue":"4","key":"3154_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040359","volume":"9","author":"TTH Thi","year":"2021","unstructured":"Thi TTH, Suys EJA, Lee JS et al (2021) Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel) 9(4):359. https:\/\/doi.org\/10.3390\/vaccines9040359","journal-title":"Vaccines (Basel)"},{"key":"3154_CR69","unstructured":"\u201cKYMRIAH|FDA.\u201d Accessed: Jun 02, 2026. [Online]. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah"},{"issue":"26","key":"3154_CR70","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3154_CR71","unstructured":"\u201cFDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia|FDA.\u201d Accessed: Jun 02, 2026. [Online]. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell"},{"issue":"1","key":"3154_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","volume":"1","author":"A Grillo-Lopez","year":"2000","unstructured":"Grillo-Lopez A et al (2000) Rituximab the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 1(1):1\u20139. https:\/\/doi.org\/10.2174\/1389201003379059","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"3154_CR73","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P et al (2021) Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia 35(1):62\u201374. https:\/\/doi.org\/10.1038\/s41375-020-0773-5","journal-title":"Leukemia"},{"issue":"7","key":"3154_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y et al (2018) CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology 7(7):e1440169. https:\/\/doi.org\/10.1080\/2162402X.2018.1440169","journal-title":"Oncoimmunology"},{"issue":"3","key":"3154_CR75","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl CA et al (2025) Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies. Clin Cancer Res 31(3):503\u2013514. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2172","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3154_CR76","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","volume":"22","author":"MY Choi","year":"2018","unstructured":"Choi MY et al (2018) Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 22(6):951-959.e3. https:\/\/doi.org\/10.1016\/j.stem.2018.05.018","journal-title":"Cell Stem Cell"},{"key":"3154_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL (2022) CD47-SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-oncol Technol 13:100070. https:\/\/doi.org\/10.1016\/j.iotech.2022.100070","journal-title":"Immuno-oncol Technol"},{"key":"3154_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","author":"D Li","year":"2023","unstructured":"Li D et al (2023) EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.adg9721","journal-title":"Sci Adv"},{"issue":"2","key":"3154_CR79","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","volume":"23","author":"A K\u00fcnkele","year":"2017","unstructured":"K\u00fcnkele A et al (2017) Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin Cancer Res 23(2):466\u2013477. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0354","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3154_CR80","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","volume":"3","author":"PD Shah","year":"2023","unstructured":"Shah PD et al (2023) Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun 3(5):821\u2013829. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0486","journal-title":"Cancer Res Commun"},{"key":"3154_CR81","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86621","author":"M Lahn","year":"2015","unstructured":"Lahn M et al (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S86621","journal-title":"Drug Des. Devel. Ther."},{"issue":"10","key":"3154_CR82","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi D et al (2018) Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer 119(10):1208\u20131214. https:\/\/doi.org\/10.1038\/s41416-018-0246-z","journal-title":"Br J Cancer"},{"issue":"1","key":"3154_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic M et al (2019) Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer 7(1):240. https:\/\/doi.org\/10.1186\/s40425-019-0706-x","journal-title":"J Immunother Cancer"},{"key":"3154_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113855","volume":"226","author":"G-J Yang","year":"2021","unstructured":"Yang G-J et al (2021) Pharmacological inhibition of KDM5A for cancer treatment. Eur J Med Chem 226:113855. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113855","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3154_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-026-07012-7","volume":"37","author":"Y Fu","year":"2026","unstructured":"Fu Y, Ge Y, Yi S et al (2026) Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability. J Mater Sci Mater Med 37(1):38. https:\/\/doi.org\/10.1007\/s10856-026-07012-7","journal-title":"J Mater Sci Mater Med"},{"key":"3154_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01614","author":"AS Choudhari","year":"2020","unstructured":"Choudhari AS, Mandave PC, Deshpande M et al (2020) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.01614","journal-title":"Front Pharmacol"},{"key":"3154_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/nu12061559","author":"D Kuran","year":"2020","unstructured":"Kuran D, Pogorzelska A, Wiktorska K (2020) Breast cancer prevention-is there a future for sulforaphane and its analogs? Nutrients. https:\/\/doi.org\/10.3390\/nu12061559","journal-title":"Nutrients"},{"issue":"18","key":"3154_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184499","volume":"15","author":"M Sarfraz","year":"2023","unstructured":"Sarfraz M et al (2023) Resveratrol-laden nano-systems in the cancer environment: views and reviews. Cancers 15(18):4499. https:\/\/doi.org\/10.3390\/cancers15184499","journal-title":"Cancers"},{"issue":"9","key":"3154_CR89","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1590\/1806-9282.63.09.810","volume":"63","author":"MAO Santos","year":"2017","unstructured":"Santos MAO, de M. Lima M (2017) CD20 role in pathophysiology of Hodgkin\u2019s disease. Rev Assoc Med Bras 63(9):810\u2013813","journal-title":"Rev Assoc Med Bras"},{"key":"3154_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363102","volume":"15","author":"A Dabkowska","year":"2024","unstructured":"Dabkowska A, Domka K, Firczuk M (2024) Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front Immunol 15:1363102. https:\/\/doi.org\/10.3389\/fimmu.2024.1363102","journal-title":"Front Immunol"},{"issue":"11","key":"3154_CR91","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/10428190412331286096","volume":"45","author":"C Nabhan","year":"2004","unstructured":"Nabhan C et al (2004) A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 45(11):2269\u20132273","journal-title":"Leuk Lymphoma"},{"key":"3154_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00895-3","author":"X Qin","year":"2026","unstructured":"Qin X, Chang Y, Qiu Y et al (2026) CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy. NPJ Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-026-00895-3","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"3154_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/17474086.2021.1935855","volume":"14","author":"MR Espinoza-Gutarra","year":"2021","unstructured":"Espinoza-Gutarra MR, Green SD, Zeidner JF et al (2021) CD123-targeted therapy in acute myeloid leukemia. Expert Rev Hematol 14(6):561\u2013576","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"3154_CR94","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I et al (2014) Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28(8):1596\u20131605","journal-title":"Leukemia"},{"key":"3154_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-018-0198-1","volume":"7","author":"PM Glumac","year":"2018","unstructured":"Glumac PM, LeBeau AM (2018) The role of CD133 in cancer: a concise review. Clin Transl Med 7:1\u201314","journal-title":"Clin Transl Med"},{"issue":"7","key":"3154_CR96","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.apsb.2020.12.015","volume":"11","author":"J Masoumi","year":"2021","unstructured":"Masoumi J et al (2021) Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: challenges and prospects. Acta Pharm Sin B 11(7):1721\u20131739","journal-title":"Acta Pharm Sin B"},{"key":"3154_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-5-67","volume":"5","author":"G Liu","year":"2006","unstructured":"Liu G et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:1\u201312","journal-title":"Mol Cancer"},{"issue":"1","key":"3154_CR98","doi-asserted-by":"publisher","first-page":"171","DOI":"10.18632\/oncotarget.2767","volume":"6","author":"X Zhu","year":"2014","unstructured":"Zhu X, Prasad S, Gaedicke S et al (2014) Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 6(1):171","journal-title":"Oncotarget"},{"issue":"Supplement_5","key":"3154_CR99","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/neuonc\/noae144.226","volume":"26","author":"Y Zhai","year":"2024","unstructured":"Zhai Y, Li G, Jiang T et al (2024) P12.13.B locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma: the first in-human clinical trial results. Neuro Oncol 26(Supplement_5):v69\u2013v69. https:\/\/doi.org\/10.1093\/neuonc\/noae144.226","journal-title":"Neuro Oncol"},{"key":"3154_CR100","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ (2019) Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev 34:26\u201333","journal-title":"Blood Rev"},{"key":"3154_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 11:1\u201313","journal-title":"J Hematol Oncol"},{"key":"3154_CR102","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F et al (2018) First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132:901","journal-title":"Blood"},{"issue":"1","key":"3154_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02239-1","volume":"10","author":"A-B Tigu","year":"2024","unstructured":"Tigu A-B et al (2024) Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov 10(1):471. https:\/\/doi.org\/10.1038\/s41420-024-02239-1","journal-title":"Cell Death Discov"},{"issue":"4","key":"3154_CR104","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1073\/pnas.1816262116","volume":"116","author":"S Zhang","year":"2019","unstructured":"Zhang S et al (2019) Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A 116(4):1370\u20131377","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"3154_CR105","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","volume":"116","author":"M Hudecek","year":"2010","unstructured":"Hudecek M et al (2010) The B-cell tumor\u2013associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22):4532\u20134541","journal-title":"Blood"},{"issue":"6","key":"3154_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128151","volume":"10","author":"DC Deniger","year":"2015","unstructured":"Deniger DC et al (2015) Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS ONE 10(6):e0128151","journal-title":"PLoS ONE"},{"issue":"7","key":"3154_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang X et al (2015) IGF1R-and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS ONE 10(7):e0133152","journal-title":"PLoS ONE"},{"issue":"6","key":"3154_CR108","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn RC et al (2016) High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30(6):1355\u20131364","journal-title":"Leukemia"},{"issue":"3","key":"3154_CR109","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S et al (2019) Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35(3):489\u2013503","journal-title":"Cancer Cell"},{"issue":"1","key":"3154_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E et al (2020) Role of CD47 in hematological malignancies. J Hematol Oncol 13(1):96. https:\/\/doi.org\/10.1186\/s13045-020-00930-1","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3154_CR111","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00277-025-06401-2","volume":"104","author":"V Sammartano","year":"2025","unstructured":"Sammartano V et al (2025) Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia. Ann Hematol 104(5):2737\u20132743. https:\/\/doi.org\/10.1007\/s00277-025-06401-2","journal-title":"Ann Hematol"},{"issue":"1","key":"3154_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010031","volume":"6","author":"BM Foster","year":"2018","unstructured":"Foster BM, Zaidi D, Young TR et al (2018) CD117\/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines 6(1):31","journal-title":"Biomedicines"},{"issue":"2","key":"3154_CR113","doi-asserted-by":"publisher","first-page":"382","DOI":"10.18203\/2349-3933.ijam20191145","volume":"6","author":"S Bhat","year":"2019","unstructured":"Bhat S, Rahim F, Geelani S et al (2019) CD 117: lineage assigning marker in acute myeloid leukemias. Int J Adv Med 6(2):382. https:\/\/doi.org\/10.18203\/2349-3933.ijam20191145","journal-title":"Int J Adv Med"},{"issue":"1","key":"3154_CR114","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/s41598-021-81126-6","volume":"11","author":"KS Harris","year":"2021","unstructured":"Harris KS et al (2021) CD117\/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. Sci Rep 11(1):1465","journal-title":"Sci Rep"},{"issue":"10","key":"3154_CR115","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","volume":"34","author":"R Myburgh","year":"2020","unstructured":"Myburgh R et al (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34(10):2688\u20132703","journal-title":"Leukemia"},{"issue":"4","key":"3154_CR116","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/hep.26168","volume":"57","author":"T Yamashita","year":"2013","unstructured":"Yamashita T et al (2013) Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 57(4):1484\u20131497","journal-title":"Hepatology"},{"issue":"24","key":"3154_CR117","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.1073\/pnas.0703478104","volume":"104","author":"P Dalerba","year":"2007","unstructured":"Dalerba P et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104(24):10158\u201310163","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3154_CR118","first-page":"4263520","volume":"2018","author":"Q Zhang","year":"2018","unstructured":"Zhang Q et al (2018) Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res 2018(1):4263520","journal-title":"J Immunol Res"},{"issue":"2","key":"3154_CR119","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jons.2017.04.002","volume":"3","author":"S Vasanthakumar","year":"2017","unstructured":"Vasanthakumar S, Sasikala P, Padma M et al (2017) EpCAM as a novel therapeutic target for hepatocellular carcinoma. J Oncol Sci 3(2):71\u201376","journal-title":"J Oncol Sci"},{"issue":"5","key":"3154_CR120","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/emboj.2011.10","volume":"30","author":"L Cheng","year":"2011","unstructured":"Cheng L et al (2011) L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 30(5):800\u2013813","journal-title":"EMBO J"},{"issue":"2","key":"3154_CR121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/CJI.0000000000000018","volume":"37","author":"H Hong","year":"2014","unstructured":"Hong H et al (2014) Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother 37(2):93\u2013104","journal-title":"J Immunother"},{"issue":"1","key":"3154_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146885","volume":"11","author":"H Hong","year":"2016","unstructured":"Hong H et al (2016) L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human T cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PLoS ONE 11(1):e0146885","journal-title":"PLoS ONE"},{"issue":"2","key":"3154_CR123","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","volume":"25","author":"A K\u00fcnkele","year":"2019","unstructured":"K\u00fcnkele A et al (2019) Manufacture of chimeric antigen receptor T cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion. Biol Blood Marrow Transpl 25(2):223\u2013232","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"3154_CR124","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1053\/j.gastro.2011.08.009","volume":"141","author":"C Li","year":"2011","unstructured":"Li C et al (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218\u20132227","journal-title":"Gastroenterology"},{"issue":"12","key":"3154_CR125","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1363137","volume":"6","author":"T Thayaparan","year":"2017","unstructured":"Thayaparan T et al (2017) CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology 6(12):e1363137","journal-title":"Oncoimmunology"},{"issue":"1","key":"3154_CR126","volume":"2012","author":"N Federman","year":"2012","unstructured":"Federman N et al (2012) Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the ALCAM cell surface receptor. Sarcoma 2012(1):126906","journal-title":"Sarcoma"},{"key":"3154_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1147-6","volume":"38","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 38:1\u201311","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"3154_CR128","first-page":"3961s","volume":"9","author":"PKE B\u00f6rjesson","year":"2003","unstructured":"B\u00f6rjesson PKE et al (2003) Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9(10):3961s\u20133972s","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3154_CR129","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","volume":"44","author":"H Riechelmann","year":"2008","unstructured":"Riechelmann H et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44(9):823\u2013829","journal-title":"Oral Oncol"},{"issue":"20","key":"3154_CR130","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","volume":"12","author":"BM Tijink","year":"2006","unstructured":"Tijink BM et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12(20):6064\u20136072. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0910","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3154_CR131","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tips.2023.11.006","volume":"45","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang H (2024) Biomarkers and targeted therapy for cancer stem cells. Trends Pharmacol Sci 45(1):56\u201366. https:\/\/doi.org\/10.1016\/j.tips.2023.11.006","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"3154_CR132","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3390\/cancers13184620","volume":"13","author":"C Larbouret","year":"2021","unstructured":"Larbouret C, Gros L, P\u00e8legrin A et al (2021) Improving biologics\u2019 effectiveness in clinical oncology: from the combination of two monoclonal antibodies to oligoclonal antibody mixtures. Cancers 13(18):4620","journal-title":"Cancers"},{"key":"3154_CR133","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.biocel.2018.08.011","volume":"103","author":"M Das","year":"2018","unstructured":"Das M, Law S (2018) Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. Int J Biochem Cell Biol 103:115\u2013124","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"3154_CR134","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1758834014548187","volume":"6","author":"AJ Dooley","year":"2014","unstructured":"Dooley AJ, Gupta A, Bhattacharyya M et al (2014) Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol 6(6):262\u2013266","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3154_CR135","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"Z-D Shi","year":"2023","unstructured":"Shi Z-D et al (2023) Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther 8(1):113","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3154_CR136","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez M et al (2016) Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 7(1):10690","journal-title":"Nat Commun"},{"issue":"4","key":"3154_CR137","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow F et al (2018) Toward minimal residual disease-directed therapy in melanoma. Cell 174(4):843\u2013855","journal-title":"Cell"},{"issue":"3","key":"3154_CR138","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski JS et al (2017) Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov 7(3):302\u2013321","journal-title":"Cancer Discov"},{"issue":"50","key":"3154_CR139","doi-asserted-by":"publisher","first-page":"20224","DOI":"10.1073\/pnas.1314239110","volume":"110","author":"J Liu","year":"2013","unstructured":"Liu J et al (2013) Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci U S A 110(50):20224\u201320229","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3154_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112909","volume":"149","author":"X Liang","year":"2022","unstructured":"Liang X, Lin A, Wang Q et al (2022) Cell plasticity in patients with NSCLC: the controversial origins of transformed SCLC. Biomed Pharmacother 149:112909","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3154_CR141","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","volume":"14","author":"L Ferrer","year":"2019","unstructured":"Ferrer L et al (2019) A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol 14(1):130\u2013134","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3154_CR142","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N et al (2019) EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 37(4):278\u2013285","journal-title":"J Clin Oncol"},{"issue":"7679","key":"3154_CR143","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ et al (2017) Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551(7679):247\u2013250","journal-title":"Nature"},{"issue":"7","key":"3154_CR144","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1878-0261.12082","volume":"11","author":"DC Voon","year":"2017","unstructured":"Voon DC, Huang RY, Jackson RA et al (2017) The EMT spectrum and therapeutic opportunities. Mol Oncol 11(7):878\u2013891","journal-title":"Mol Oncol"},{"key":"3154_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.614468","volume":"10","author":"T Baram","year":"2021","unstructured":"Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H et al (2021) Inflammation-driven breast tumor cell plasticity: stemness\/EMT, therapy resistance and dormancy. Front Oncol 10:614468","journal-title":"Front Oncol"},{"key":"3154_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C (2021) Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther 219:107692","journal-title":"Pharmacol Ther"},{"issue":"7","key":"3154_CR147","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440166","volume":"7","author":"P Xiao","year":"2018","unstructured":"Xiao P et al (2018) Neurotensin\/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of tumor-associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. Oncoimmunology 7(7):e1440166","journal-title":"Oncoimmunology"},{"issue":"11","key":"3154_CR148","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/1535-7163.MCT-19-0004","volume":"18","author":"DC Kahraman","year":"2019","unstructured":"Kahraman DC, Kahraman T, Cetin-Atalay R (2019) Targeting PI3K\/Akt\/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment. Mol Cancer Ther 18(11):2146\u20132157","journal-title":"Mol Cancer Ther"},{"key":"3154_CR149","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94296","author":"C Dominguez","year":"2017","unstructured":"Dominguez C, McCampbell KK, David JM et al (2017) Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.94296","journal-title":"JCI Insight"},{"issue":"27","key":"3154_CR150","doi-asserted-by":"publisher","first-page":"42031","DOI":"10.18632\/oncotarget.9662","volume":"7","author":"RI Fernando","year":"2016","unstructured":"Fernando RI, Hamilton DH, Dominguez C et al (2016) IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget 7(27):42031","journal-title":"Oncotarget"},{"issue":"9","key":"3154_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139237","volume":"10","author":"B Devapatla","year":"2015","unstructured":"Devapatla B, Sharma A, Woo S (2015) CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer. PLoS ONE 10(9):e0139237","journal-title":"PLoS ONE"},{"issue":"6","key":"3154_CR152","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","volume":"26","author":"S Greene","year":"2020","unstructured":"Greene S et al (2020) Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models. Clin Cancer Res 26(6):1420\u20131431","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3154_CR153","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126853","volume":"4","author":"L Sun","year":"2019","unstructured":"Sun L et al (2019) Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 4(7):e126853","journal-title":"JCI Insight"},{"key":"3154_CR154","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ebiom.2018.10.069","volume":"38","author":"Y Qin","year":"2018","unstructured":"Qin Y et al (2018) Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1\u03b1 signaling pathway. EBioMedicine 38:25\u201336","journal-title":"EBioMedicine"},{"key":"3154_CR155","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2017.11.037","volume":"415","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-\u03baB mediated epithelial\u2013mesenchymal transition and stemness. Cancer Lett 415:73\u201385","journal-title":"Cancer Lett"},{"issue":"7","key":"3154_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072106","volume":"27","author":"MJ Kim","year":"2022","unstructured":"Kim MJ et al (2022) Reduced HIF-1\u03b1 stability induced by 6-gingerol inhibits lung cancer growth through the induction of cell death. Molecules 27(7):2106","journal-title":"Molecules"},{"issue":"14","key":"3154_CR157","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2217\/fon-2021-0862","volume":"18","author":"Y Chen","year":"2022","unstructured":"Chen Y et al (2022) Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol 18(14):1757\u20131775","journal-title":"Future Oncol"},{"issue":"7","key":"3154_CR158","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani K et al (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28(7):1532\u20131539","journal-title":"Ann Oncol"},{"issue":"1","key":"3154_CR159","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA et al (2013) An epithelial\u2013mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279\u2013290","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3154_CR160","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu J, Lamouille S, Derynck R (2009) TGF-\u03b2-induced epithelial to mesenchymal transition. Cell Res 19(2):156\u2013172","journal-title":"Cell Res"},{"issue":"1","key":"3154_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19920-5","volume":"11","author":"AL Grauel","year":"2020","unstructured":"Grauel AL et al (2020) TGF\u03b2-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nat Commun 11(1):6315","journal-title":"Nat Commun"},{"issue":"1","key":"3154_CR162","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1257453","volume":"6","author":"A de Gramont","year":"2017","unstructured":"de Gramont A, Faivre S, Raymond E (2017) Novel TGF-\u03b2 inhibitors ready for prime time in onco-immunology. Oncoimmunology 6(1):e1257453","journal-title":"Oncoimmunology"},{"issue":"4","key":"3154_CR163","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK et al (2014) Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 13(4):842\u2013854","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"3154_CR164","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41419-019-2143-7","volume":"10","author":"M Gagliardi","year":"2019","unstructured":"Gagliardi M et al (2019) Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis 10(12):902","journal-title":"Cell Death Dis"},{"issue":"1","key":"3154_CR165","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-021-00702-4","volume":"6","author":"J Xie","year":"2021","unstructured":"Xie J et al (2021) Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma. Signal Transduct Target Ther 6(1):333","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3154_CR166","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2021.11.010","volume":"76","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. J Hepatol 76(3):652\u2013664","journal-title":"J Hepatol"},{"issue":"579","key":"3154_CR167","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6282","volume":"13","author":"F-E Kong","year":"2021","unstructured":"Kong F-E et al (2021) Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med 13(579):eabb6282","journal-title":"Sci Transl Med"},{"key":"3154_CR168","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181575","author":"F Huang","year":"2024","unstructured":"Huang F et al (2024) Inhibiting the MNK1\/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI181575","journal-title":"J Clin Invest"},{"issue":"5","key":"3154_CR169","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.celrep.2014.07.050","volume":"8","author":"HS Leong","year":"2014","unstructured":"Leong HS et al (2014) Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep 8(5):1558\u20131570","journal-title":"Cell Rep"},{"issue":"19","key":"3154_CR170","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791","journal-title":"N Engl J Med"},{"issue":"24","key":"3154_CR171","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1111\/bph.12704","volume":"171","author":"CM Fife","year":"2014","unstructured":"Fife CM, McCarroll JA, Kavallaris M (2014) Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 171(24):5507\u20135523","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3154_CR172","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14737140.2020.1718496","volume":"20","author":"K Stoletov","year":"2020","unstructured":"Stoletov K, Beatty PH, Lewis JD (2020) Novel therapeutic targets for cancer metastasis. Expert Rev Anticancer Ther 20(2):97\u2013109","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3154_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/srep42186","volume":"7","author":"A Takemoto","year":"2017","unstructured":"Takemoto A et al (2017) A critical role of platelet TGF-\u03b2 release in podoplanin-mediated tumour invasion and metastasis. Sci Rep 7(1):42186","journal-title":"Sci Rep"},{"issue":"1","key":"3154_CR174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sdata.2017.129","volume":"4","author":"L Van Der Weyden","year":"2017","unstructured":"Van Der Weyden L, Karp NA, Swiatkowska A et al (2017) Genome wide in vivo mouse screen data from studies to assess host regulation of metastatic colonisation. Sci Data 4(1):1\u20137","journal-title":"Sci Data"},{"issue":"4","key":"3154_CR175","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450\u2013461","journal-title":"Cancer Cell"},{"issue":"4","key":"3154_CR176","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/bjc.2011.9","volume":"104","author":"BH Kang","year":"2011","unstructured":"Kang BH et al (2011) Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer 104(4):629\u2013634","journal-title":"Br J Cancer"},{"key":"3154_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-431","volume":"14","author":"H-K Park","year":"2014","unstructured":"Park H-K et al (2014) Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim. BMC Cancer 14:1\u20139","journal-title":"BMC Cancer"},{"issue":"3","key":"3154_CR178","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccr.2008.01.031","volume":"13","author":"A Zijlstra","year":"2008","unstructured":"Zijlstra A, Lewis J, DeGryse B et al (2008) The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13(3):221\u2013234","journal-title":"Cancer Cell"},{"issue":"13","key":"3154_CR179","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1128\/MCB.24.13.5978-5988.2004","volume":"24","author":"MD Wright","year":"2004","unstructured":"Wright MD et al (2004) Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24(13):5978\u20135988","journal-title":"Mol Cell Biol"},{"issue":"10","key":"3154_CR180","doi-asserted-by":"publisher","first-page":"275","DOI":"10.15698\/cst2018.10.159","volume":"2","author":"K Stoletov","year":"2018","unstructured":"Stoletov K, Willetts L, Beatty PH et al (2018) Intravital imaging tumor screen used to identify novel metastasis-blocking therapeutic targets. Cell Stress 2(10):275","journal-title":"Cell Stress"},{"issue":"2","key":"3154_CR181","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3171\/2016.1.JNS152075","volume":"126","author":"S Ohtaki","year":"2017","unstructured":"Ohtaki S et al (2017) ACTC1 as an invasion and prognosis marker in glioma. J Neurosurg 126(2):467\u2013475","journal-title":"J Neurosurg"},{"issue":"22","key":"3154_CR182","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41388-018-0180-9","volume":"37","author":"Z-C Zhu","year":"2018","unstructured":"Zhu Z-C, Liu J-W, Li K et al (2018) KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells. Oncogene 37(22):2936\u20132952","journal-title":"Oncogene"},{"issue":"1","key":"3154_CR183","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ymthe.2016.10.009","volume":"25","author":"N Nishida-Aoki","year":"2017","unstructured":"Nishida-Aoki N, Tominaga N, Takeshita F et al (2017) Disruption of circulating extracellular vesicles as a novel therapeutic strategy against cancer metastasis. Mol Ther 25(1):181\u2013191","journal-title":"Mol Ther"},{"issue":"7","key":"3154_CR184","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/toxins8070199","volume":"8","author":"J Oh","year":"2016","unstructured":"Oh J, Hlatky L, Jeong Y-S et al (2016) Therapeutic effectiveness of anticancer phytochemicals on cancer stem cells. Toxins 8(7):199","journal-title":"Toxins"},{"key":"3154_CR185","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3389\/fpls.2016.01667","volume":"7","author":"S Singh","year":"2016","unstructured":"Singh S, Sharma B, Kanwar SS et al (2016) Lead phytochemicals for anticancer drug development. Front Plant Sci 7:1667","journal-title":"Front Plant Sci"},{"issue":"5","key":"3154_CR186","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3390\/molecules24050899","volume":"24","author":"A Liskova","year":"2019","unstructured":"Liskova A et al (2019) Dietary phytochemicals targeting cancer stem cells. Molecules 24(5):899","journal-title":"Molecules"},{"key":"3154_CR187","volume":"3","author":"A Roy","year":"2013","unstructured":"Roy A, Ray M, Jana K (2013) Cancer stem cells, Wnt, hedgehog and notch signaling, the role of dietary phytochemicals: new insights for cancer therapy. Transl Med 3:e125","journal-title":"Transl Med"},{"key":"3154_CR188","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.fct.2014.11.004","volume":"75","author":"F Pistollato","year":"2015","unstructured":"Pistollato F, Giampieri F, Battino M (2015) The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment. Food Chem Toxicol 75:58\u201370","journal-title":"Food Chem Toxicol"},{"key":"3154_CR189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/scrt506","volume":"5","author":"S Mukherjee","year":"2014","unstructured":"Mukherjee S et al (2014) Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin\/\u03b2-catenin negative feedback loop. Stem Cell Res Ther 5:1\u201319","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3154_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016530","volume":"6","author":"S Shankar","year":"2011","unstructured":"Shankar S et al (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 6(1):e16530","journal-title":"PLoS ONE"},{"issue":"1","key":"3154_CR191","doi-asserted-by":"publisher","first-page":"3189217","DOI":"10.1155\/2020\/3189217","volume":"2020","author":"K Yang","year":"2020","unstructured":"Yang K et al (2020) Curcumin and glu-GNPs induce radiosensitivity against breast cancer stem-like cells. Biomed Res Int 2020(1):3189217","journal-title":"Biomed Res Int"},{"issue":"7","key":"3154_CR192","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1002\/jcb.26796","volume":"119","author":"M Hashemzehi","year":"2018","unstructured":"Hashemzehi M et al (2018) Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-kinase in breast cancer. J Cell Biochem 119(7):5996\u20136007","journal-title":"J Cell Biochem"},{"issue":"1","key":"3154_CR193","first-page":"39","volume":"35","author":"SS Chung","year":"2015","unstructured":"Chung SS, Vadgama JV (2015) Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3\u2013NF\u03baB signaling. Anticancer Res 35(1):39\u201346","journal-title":"Anticancer Res"},{"issue":"3","key":"3154_CR194","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1061186X.2016.1242132","volume":"25","author":"M Ren","year":"2017","unstructured":"Ren M, Wang Y, Wu X et al (2017) Curcumin synergistically increases effects of \u03b2-interferon and retinoic acid on breast cancer cells in vitro and in vivo by up-regulation of GRIM-19 through STAT3-dependent and STAT3-independent pathways. J Drug Target 25(3):247\u2013254","journal-title":"J Drug Target"},{"issue":"1","key":"3154_CR195","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41523-020-00178-5","volume":"6","author":"DS Peiffer","year":"2020","unstructured":"Peiffer DS, Ma E, Wyatt D et al (2020) DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development. NPJ Breast Cancer 6(1):37","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"3154_CR196","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/mnfr.201200549","volume":"57","author":"K Mak","year":"2013","unstructured":"Mak K et al (2013) Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-\u03ba B\/microRNA 448 circuit. Mol Nutr Food Res 57(7):1123\u20131134","journal-title":"Mol Nutr Food Res"},{"issue":"8","key":"3154_CR197","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/ptr.6081","volume":"32","author":"S Li","year":"2018","unstructured":"Li S, Zhao Q, Wang B et al (2018) Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation. Phytother Res 32(8):1530\u20131536","journal-title":"Phytother Res"},{"issue":"6","key":"3154_CR198","first-page":"1703","volume":"27","author":"Y Imai","year":"2012","unstructured":"Imai Y, Yoshimori M, Fukuda K et al (2012) The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep 27(6):1703\u20131709","journal-title":"Oncol Rep"},{"key":"3154_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116938","volume":"238","author":"E Zhang","year":"2019","unstructured":"Zhang E et al (2019) \u201c7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer,.\u201d Life Sci 238:116938","journal-title":"Life Sci"},{"issue":"3","key":"3154_CR200","first-page":"1625","volume":"42","author":"L Cao","year":"2018","unstructured":"Cao L et al (2018) Quercetin-3-methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K\/Akt signaling pathways. Int J Mol Med 42(3):1625\u20131636","journal-title":"Int J Mol Med"},{"issue":"1","key":"3154_CR201","first-page":"29","volume":"2","author":"L-L Ting","year":"2016","unstructured":"Ting L-L, Chou AS-B, Hsieh C-H et al (2016) Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model. J. Cancer Metastasis Treat 2(1):29\u201340","journal-title":"J. Cancer Metastasis Treat"},{"issue":"2","key":"3154_CR202","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1158\/0008-5472.CAN-09-1681","volume":"70","author":"H Harrison","year":"2010","unstructured":"Harrison H et al (2010) \u201cRegulation of breast cancer stem cell activity by signaling through the Notch4 receptor,.\u201d Cancer Res 70(2):709\u2013718","journal-title":"Cancer Res"},{"issue":"7","key":"3154_CR203","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/1940-6207.CAPR-13-0445","volume":"7","author":"S-H Kim","year":"2014","unstructured":"Kim S-H, Singh SV (2014) Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res 7(7):738\u2013747","journal-title":"Cancer Prev Res"},{"issue":"10","key":"3154_CR204","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s13205-021-02994-3","volume":"11","author":"KS Prajapati","year":"2021","unstructured":"Prajapati KS, Shuaib M, Kushwaha PP et al (2021) Identification of cancer stemness related miRNA (s) using integrated bioinformatics analysis and in vitro validation. 3 Biotech 11(10):446","journal-title":"3 Biotech"},{"key":"3154_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109200","volume":"328","author":"PP Kushwaha","year":"2020","unstructured":"Kushwaha PP et al (2020) 3-O-(E)-p-Coumaroyl betulinic acid possess anticancer activity and inhibit Notch signaling pathway in breast cancer cells and mammosphere. Chem Biol Interact 328:109200","journal-title":"Chem Biol Interact"},{"key":"3154_CR206","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2017.10.029","volume":"413","author":"S Kumar","year":"2018","unstructured":"Kumar S et al (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82\u201393","journal-title":"Cancer Lett"},{"issue":"6","key":"3154_CR207","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/ijms19061754","volume":"19","author":"B Paul","year":"2018","unstructured":"Paul B, Li Y, Tollefsbol TO (2018) The effects of combinatorial genistein and sulforaphane in breast tumor inhibition: role in epigenetic regulation. Int J Mol Sci 19(6):1754","journal-title":"Int J Mol Sci"},{"key":"3154_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/scrt357","author":"P Fan","year":"2013","unstructured":"Fan P et al (2013) Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway. Stem Cell Res Ther. https:\/\/doi.org\/10.1186\/scrt357","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"3154_CR209","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ph12010011","volume":"12","author":"B Salehi","year":"2019","unstructured":"Salehi B et al (2019) The therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals 12(1):11","journal-title":"Pharmaceuticals"},{"issue":"1","key":"3154_CR210","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/TUB-211506","volume":"43","author":"MA Askar","year":"2021","unstructured":"Askar MA, El Shawi OE, Mansour NA et al (2021) Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: in vitro and in vivo studies. Tumour Biol 43(1):225\u2013247","journal-title":"Tumour Biol"},{"issue":"10","key":"3154_CR211","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jnutbio.2011.07.003","volume":"23","author":"L Ye","year":"2012","unstructured":"Ye L, Chan FL, Chen S et al (2012) The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice. J Nutr Biochem 23(10):1230\u20131237","journal-title":"J Nutr Biochem"},{"key":"3154_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00010","volume":"6","author":"RA Rather","year":"2018","unstructured":"Rather RA, Bhagat M (2018) Cancer chemoprevention and piperine: molecular mechanisms and therapeutic opportunities. Front Cell Dev Biol 6:10","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3154_CR213","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbrc.2012.06.062","volume":"424","author":"A Semov","year":"2012","unstructured":"Semov A et al (2012) Diindolilmethane (DIM) selectively inhibits cancer stem cells. Biochem Biophys Res Commun 424(1):45\u201351","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"3154_CR214","doi-asserted-by":"publisher","first-page":"20667","DOI":"10.18632\/oncotarget.15400","volume":"8","author":"G Bonuccelli","year":"2017","unstructured":"Bonuccelli G, De Francesco EM, de Boer R et al (2017) NADH autofluorescence, a new metabolic biomarker for cancer stem cells: identification of Vitamin C and CAPE as natural products targeting \u2018stemness.\u2019 Oncotarget 8(13):20667","journal-title":"Oncotarget"},{"issue":"11","key":"3154_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129695","volume":"1864","author":"M Bhattacharjee","year":"1864","unstructured":"Bhattacharjee M et al (1864) Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. Biochim et Biophys Acta (BBA)-Gen Subj 1864(11):129695","journal-title":"Biochim et Biophys Acta (BBA)-Gen Subj"},{"key":"3154_CR216","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.phrs.2017.11.027","volume":"129","author":"B Cevatemre","year":"2018","unstructured":"Cevatemre B et al (2018) A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer. Pharmacol Res 129:500\u2013514","journal-title":"Pharmacol Res"},{"issue":"3","key":"3154_CR217","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jgr.2018.05.004","volume":"43","author":"J Oh","year":"2019","unstructured":"Oh J, Yoon H-J, Jang J-H et al (2019) The standardized Korean Red Ginseng extract and its ingredient ginsenoside Rg3 inhibit manifestation of breast cancer stem cell\u2013like properties through modulation of self-renewal signaling. J Ginseng Res 43(3):421\u2013430","journal-title":"J Ginseng Res"},{"issue":"1\u20132","key":"3154_CR218","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijpharm.2018.01.016","volume":"538","author":"F Dilnawaz","year":"2018","unstructured":"Dilnawaz F, Acharya S, Sahoo SK (2018) Recent trends of nanomedicinal approaches in clinics. Int J Pharm 538(1\u20132):263\u2013278","journal-title":"Int J Pharm"},{"issue":"3","key":"3154_CR219","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/17425240902780166","volume":"6","author":"M Das","year":"2009","unstructured":"Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6(3):285\u2013304","journal-title":"Expert Opin Drug Deliv"},{"issue":"13\u201314","key":"3154_CR220","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.addr.2013.09.016","volume":"65","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Alakhova DY, Kabanov AV (2013) Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 65(13\u201314):1763\u20131783","journal-title":"Adv Drug Deliv Rev"},{"key":"3154_CR221","doi-asserted-by":"publisher","first-page":"1121950","DOI":"10.3389\/fphar.2023.1121950","volume":"14","author":"L Koklesova","year":"2023","unstructured":"Koklesova L et al (2023) Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management\u2014targeting cancer stem cells in the framework of predictive, preventive, personalized medicine. Front Pharmacol 14:1121950","journal-title":"Front Pharmacol"},{"key":"3154_CR222","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060862","author":"A Schulz","year":"2019","unstructured":"Schulz A, Meyer F, Dubrovska A et al (2019) Cancer stem cells and radioresistance: DNA repair and beyond. Cancers. https:\/\/doi.org\/10.3390\/cancers11060862","journal-title":"Cancers"},{"issue":"3","key":"3154_CR223","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0360-3016(99)00170-4","volume":"45","author":"M Mohiuddin","year":"1999","unstructured":"Mohiuddin M, Fujita M, Regine WF et al (1999) High-dose spatially-fractionated radiation (GRID): a new paradigm in the management of advanced cancers. Int J Radiat Oncol Biol Phys 45(3):721\u2013727","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3154_CR224","first-page":"30","volume":"20","author":"W Yan","year":"2020","unstructured":"Yan W et al (2020) Spatially fractionated radiation therapy: history, present and the future. Clin Transl Radiat Oncol 20:30\u201338","journal-title":"Clin Transl Radiat Oncol"},{"issue":"6","key":"3154_CR225","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1667\/RADE-20-00066.1","volume":"194","author":"X Wu","year":"2020","unstructured":"Wu X et al (2020) The technical and clinical implementation of LATTICE radiation therapy (LRT). Radiat Res 194(6):737\u2013746","journal-title":"Radiat Res"},{"issue":"2","key":"3154_CR226","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijrobp.2019.01.080","volume":"104","author":"Y Prezado","year":"2019","unstructured":"Prezado Y et al (2019) Tumor control in RG2 glioma-bearing rats: a comparison between proton minibeam therapy and standard proton therapy. Int J Radiat Oncol Biol Phys 104(2):266\u2013271","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"3154_CR227","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1073\/pnas.0603567103","volume":"103","author":"FA Dilmanian","year":"2006","unstructured":"Dilmanian FA et al (2006) Interlaced x-ray microplanar beams: a radiosurgery approach with clinical potential. Proc Natl Acad Sci U S A 103(25):9709\u20139714","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3154_CR228","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2019.06.030","volume":"139","author":"L Eling","year":"2019","unstructured":"Eling L et al (2019) Ultra high dose rate synchrotron microbeam radiation therapy. Preclinical evidence in view of a clinical transfer. Radiother Oncol 139:56\u201361","journal-title":"Radiother Oncol"},{"issue":"22","key":"3154_CR229","doi-asserted-by":"publisher","first-page":"10943","DOI":"10.1073\/pnas.1901777116","volume":"116","author":"P Montay-Gruel","year":"2019","unstructured":"Montay-Gruel P et al (2019) Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci U S A 116(22):10943\u201310951","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3154_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A et al (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 21(1):62","journal-title":"Cancer Cell Int"},{"key":"3154_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1495216","volume":"14","author":"YK Lee","year":"2024","unstructured":"Lee YK et al (2024) A preliminary study of linear accelerator-based spatially fractionated radiotherapy. Front Oncol 14:1495216. https:\/\/doi.org\/10.3389\/fonc.2024.1495216","journal-title":"Front Oncol"},{"issue":"11","key":"3154_CR232","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206693","volume":"13","author":"M Potez","year":"2018","unstructured":"Potez M et al (2018) Characterization of a B16\u2013F10 melanoma model locally implanted into the ear pinnae of C57BL\/6 mice. PLoS ONE 13(11):e0206693","journal-title":"PLoS ONE"},{"issue":"5","key":"3154_CR233","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ijrobp.2019.08.027","volume":"105","author":"M Potez","year":"2019","unstructured":"Potez M et al (2019) Synchrotron microbeam radiation therapy as a new approach for the treatment of radioresistant melanoma: potential underlying mechanisms. Int J Radiat Oncol Biol Phys 105(5):1126\u20131136","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"3154_CR234","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.3390\/cancers12092656","volume":"12","author":"C Fernandez-Palomo","year":"2020","unstructured":"Fernandez-Palomo C et al (2020) Complete remission of mouse melanoma after temporally fractionated microbeam radiotherapy. Cancers 12(9):2656","journal-title":"Cancers"},{"issue":"10","key":"3154_CR235","doi-asserted-by":"publisher","first-page":"10TR02","DOI":"10.1088\/1361-6560\/ad4192","volume":"69","author":"Y Prezado","year":"2024","unstructured":"Prezado Y et al (2024) Spatially fractionated radiation therapy: a critical review on current status of clinical and preclinical studies and knowledge gaps. Phys Med Biol 69(10):10TR02. https:\/\/doi.org\/10.1088\/1361-6560\/ad4192","journal-title":"Phys Med Biol"},{"issue":"10","key":"3154_CR236","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/cancers9100139","volume":"9","author":"V Golubovskaya","year":"2017","unstructured":"Golubovskaya V et al (2017) CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers 9(10):139","journal-title":"Cancers"},{"issue":"1\u20132","key":"3154_CR237","first-page":"64","volume":"39","author":"H Sarkar","year":"2025","unstructured":"Sarkar H, Lee E, Lopez-Darwin SL et al (2025) Deciphering normal and cancer stem cell niches by spatial transcriptomics: opportunities and challenges. Genes Dev 39(1\u20132):64\u201385","journal-title":"Genes Dev"},{"key":"3154_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102751","author":"J Li","year":"2026","unstructured":"Li J et al (2026) Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Rep Med. https:\/\/doi.org\/10.1016\/j.xcrm.2026.102751","journal-title":"Cell Rep Med"},{"key":"3154_CR239","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1214425","author":"J Chen","year":"2023","unstructured":"Chen J, Xu L, Li X et al (2023) Deep learning models for cancer stem cell detection: a brief review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1214425","journal-title":"Front Immunol"},{"key":"3154_CR240","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf566","author":"X Huang","year":"2025","unstructured":"Huang X et al (2025) Single-cell multi-omics and machine learning for dissecting stemness in cancer. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbaf566","journal-title":"Brief Bioinform"},{"issue":"24","key":"3154_CR241","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17244025","volume":"17","author":"AK Gorbushin","year":"2025","unstructured":"Gorbushin AK et al (2025) Drug-induced partial immunosuppression for preclinical human tumor xenograft models. Cancers 17(24):4025. https:\/\/doi.org\/10.3390\/cancers17244025","journal-title":"Cancers"},{"issue":"1","key":"3154_CR242","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H et al (2025) Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther 10(1):248","journal-title":"Signal Transduct Target Ther"},{"key":"3154_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116214","volume":"172","author":"O Pendor","year":"2026","unstructured":"Pendor O, Ukey S, Kurjekar D et al (2026) Nanotheratrack: precision nanomedicine for diagnosis & therapy. Int Immunopharmacol 172:116214. https:\/\/doi.org\/10.1016\/j.intimp.2026.116214","journal-title":"Int Immunopharmacol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03154-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:53:34Z","timestamp":1787669614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03154-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":243,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03154-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There exists no conflict of interest pertaining to the publication of this manuscript in your esteemed Journal.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors gave their due consent to publish the said manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}